Raffaella Sordella;Daniel A. Haber;Jeffrey E. Settleman;Sridhar Krishna Rabindran;Nadia G. Godin-Heymann;Daphne Winifred Bell;Eunice L. Kwak
发明人:
Daniel A. Haber,Daphne Winifred Bell,Jeffrey E. Settleman,Raffaella Sordella,Nadia G. Godin-Heymann,Eunice L. Kwak,Sridhar Krishna Rabindran
申请号：
US11883474
公开号：
US10603314B2
申请日:
2006.02.02
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
